ArticleJournal of hepatology2015
3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
Article in Journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- Effect of hypoxia-inducible factor 1 alpha inhibitor on immobilization-induced muscle fibrosis related to muscle contracture.Journal of physical therapy science · 2025Article
- Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis.Npj imaging · 2025Article
- FAP-catalyzed in situ self-assembly of magnetic resonance imaging probe for early and precise staging of liver fibrosis.Science advances · 2025Article
- Simultaneous Positron Emission Tomography and Molecular Magnetic Resonance Imaging of Cardiopulmonary Fibrosis in a Mouse Model of Left Ventricular Dysfunction.Journal of the American Heart Association · 2024Article
- Platelet-derived growth factor receptor β-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis.European journal of nuclear medicine and molecular imaging · 2024Article
- Molecular Imaging of Fibrosis in Benign Diseases: An Overview of the State of the Art.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies.Theranostics · 2024Article
- Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.Biomaterials research · 2024Review
- Biased Quantification of Rat Liver Fibrosis-Meta-Analysis with Practical Recommendations and Clinical Implications.Journal of clinical medicine · 2023Article
- Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment.Science translational medicine · 2022Article
- Genomic miscellany and allelic frequencies of Plasmodium falciparum msp-1, msp-2 and glurp in parasite isolates.PloS one · 2022Article
- Multiparameter magnetic resonance imaging of liver fibrosis in a bile duct ligation mouse model.World journal of gastroenterology · 2021Article
- Article
- Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.Scientific reports · 2021Article
- A Type I Collagen-Targeted MR Imaging Probe for Staging Fibrosis in Crohn's Disease.Frontiers in molecular biosciences · 2021Article
- Use of EP3533-Enhanced Magnetic Resonance Imaging as a Measure of Disease Progression in Skeletal Muscle ofFrontiers in neurology · 2021Article
- Advances in functional and molecular MRI technologies in chronic liver diseases.Journal of hepatology · 2020Review
- Toward Molecular Imaging of Intestinal Pathology.Inflammatory bowel diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsLiver biopsy, the gold standard for assessing liver fibrosis, suffers from limitations due to sampling error and invasiveness. There is therefore a critical need for methods to non-invasively quantify fibrosis throughout the entire liver. The goal of this study was to use molecular Magnetic Resonance Imaging (MRI) of Type I collagen to non-invasively image liver fibrosis and assess response to rapamycin therapy.
methodsLiver fibrosis was induced in rats by bile duct ligation (BDL). MRI was performed 4, 10, or 18 days following BDL. Some BDL rats were treated daily with rapamycin starting on day 4 and imaged on day 18. A three-dimensional (3D) inversion recovery MRI sequence was used to quantify the change in liver longitudinal relaxation rate (ΔR1) induced by the collagen-targeted probe EP-3533. Liver tissue was subjected to pathologic scoring of fibrosis and analyzed for Sirius Red staining and hydroxyproline content.
resultsΔR1 increased significantly with time following BDL compared to controls in agreement with ex vivo measures of increasing fibrosis. Receiver operating characteristic curve analysis demonstrated the ability of ΔR1 to detect liver fibrosis and distinguish intermediate and late stages of fibrosis. EP-3533 MRI correctly characterized the response to rapamycin in 11 out of 12 treated rats compared to the standard of collagen proportional area (CPA). 3D MRI enabled characterization of disease heterogeneity throughout the whole liver.
conclusionsEP-3533 allowed for staging of liver fibrosis, assessment of response to rapamycin therapy, and demonstrated the ability to detect heterogeneity in liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.